ADP-ribosylhydrolase (ADPRH), also known as ARH3. is a conserved enzyme critical for regulating post-translational protein modifications involving ADP-ribosylation. This reversible process, mediated by poly(ADP-ribose) polymerases (PARPs) and hydrolyzed by ADPRH, plays roles in DNA repair, chromatin remodeling, and cellular stress responses. Dysregulation of ADP-ribosylation is linked to neurodegenerative diseases, cancer, and inflammation, making ADPRH a key research target.
Recombinant ADPRH protein, produced via heterologous expression systems like *E. coli* or mammalian cells, enables mechanistic studies and therapeutic exploration. Its production involves cloning the ADPRH gene into expression vectors, optimizing conditions for solubility and yield, and purifying the protein using affinity chromatography. Recombinant ADPRH retains enzymatic activity, allowing *in vitro* assays to study substrate specificity, interaction partners, and inhibitors.
Research using recombinant ADPRH has clarified its role in removing ADP-ribose moieties from proteins, particularly in resolving neurotoxic accumulations linked to Parkinson’s and Alzheimer’s diseases. It also modulates PARP1-driven inflammation, suggesting therapeutic potential in autoimmune disorders. Structural studies of recombinant ADPRH have identified catalytic residues and guided drug design efforts to target ADP-ribosylation pathways.
Overall, recombinant ADPRH serves as a vital tool for deciphering ADP-ribosylation biology and developing precision therapies for related diseases. Its applications span basic enzymology, disease modeling, and high-throughput drug screening.
以下是3篇与ADPRS重组蛋白相关的模拟参考文献(注：文献为示例，非真实存在)：
---
1. **文献名称**：*Expression and Functional Characterization of Recombinant ADP-ribosyltransferase (ADPRS) in E. coli*
**作者**：Lee, J. et al.
**摘要**：本研究成功在大肠杆菌中表达了重组ADPRS蛋白，并通过亲和层析纯化获得高纯度产物。酶活性分析表明，重组ADPRS具有催化NAD+转化为ADP-核糖聚合物的能力，为后续药物靶点研究奠定基础。
---
2. **文献名称**：*Structural Insights into ADPRS Catalytic Mechanism via Crystallography*
**作者**：Zhang, R. & Patel, S.
**摘要**：通过X射线晶体学解析了重组ADPRS的三维结构，揭示了其底物结合位点及催化关键氨基酸残基。该研究阐明了ADPRS在DNA损伤修复中的分子机制，为设计特异性抑制剂提供依据。
---
3. **文献名称**：*ADPRS Recombinant Protein Enhances Cellular Resistance to Oxidative Stress*
**作者**：Gomez, M.A. et al.
**摘要**：利用哺乳动物细胞表达系统制备重组ADPRS，实验证明其过表达显著提升细胞对氧化应激的耐受性，机制可能与PARP信号通路调控相关，提示其在治疗退行性疾病中的潜在价值。
---
如需真实文献，建议通过PubMed或Web of Science检索关键词：**"ADP-ribosyltransferase recombinant"** 或 **"recombinant CD38/ADPR cyclase"**。
ADPRS (ADP-ribosyltransferase) recombinant proteins are engineered versions of enzymes involved in the transfer of ADP-ribose moieties to target molecules, a post-translational modification critical for numerous cellular processes. These proteins are derived from genes encoding ADP-ribosyltransferases, which are part of the larger PARP (poly-ADP-ribose polymerase) family. ADP-ribosylation regulates DNA repair, chromatin remodeling, apoptosis, and immune responses, making these enzymes essential for maintaining genomic stability and cellular homeostasis.
The development of recombinant ADPRS proteins leverages genetic engineering to express and purify these enzymes in heterologous systems, such as *E. coli* or mammalian cell cultures. This approach ensures high yield, purity, and activity, enabling detailed biochemical and structural studies. Recombinant ADPRS proteins are pivotal in dissecting mechanisms of ADP-ribosylation, identifying substrate specificity, and exploring interactions with partner proteins. They also serve as tools for screening inhibitors, which have therapeutic potential in cancer, neurodegenerative diseases, and inflammation.
Interest in ADPRS has surged due to their roles in DNA damage response pathways. For example, PARP1. a well-studied member, is a target for anticancer drugs that exploit synthetic lethality in BRCA-deficient tumors. Recombinant forms allow researchers to study enzyme kinetics, catalytic domains, and the impact of mutations on function. Additionally, atypical ADP-ribosyltransferases, such as ARTCs and ARTHs, are investigated for their involvement in bacterial toxicity and cell signaling.
Overall, ADPRS recombinant proteins bridge basic research and clinical applications, offering insights into disease mechanisms and accelerating drug discovery. Their versatility underscores their importance in both academic and industrial settings.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
